Dr. Carol A Tamminga, MD
Claim this profileUniversity of Texas Southwestern Medical Center
Studies Schizophrenia
Studies High Risk for Psychosis
3 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Carol A Tamminga, MD is currently running
Deep Brain Stimulation
for Schizophrenia
There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment. 2) Investigators will successfully model psychotic versus non-psychotic brain states using support vector machine (SVM) classifiers. 3) Participants specific brain stimulation parameters can induce a change in the brain state consistent with non-psychotic states as measured by classifier output. Hypotheses 1, 2, and 3 address safety and tolerability, efficacy, and the putative mechanism of successful treatment. The overall objective is to use next generation Deep Brain Stimulation (DBS) combined with antecedent stereo electroencephalogram (SEEG) mapping to establish a new therapy for treatment-refractory schizophrenia given the limitations of current treatment modalities. The primary objective is to demonstrate safety of acute and chronic network guided stimulation for treatment-refractory schizophrenia. Exploratory Objectives: 1. Use intracranial mapping (SEEG) combined with pharmacological manipulation of psychotic states to create a protocol for participant specific deep brain stimulation to treat treatment-refractory schizophrenia. 2. Develop closed loop stimulation protocols to modify brain states during psychotic brain activity induced by low-dose ketamine administration. 3. Investigate the use of mnemonic similarity to characterize brain networks related to symptoms of treatment-refractory schizophrenia. 4. Treatment-related objectives: Record a reduction in psychotic symptoms, as well as an improvement in psychosocial function and cognition.
Recruiting1 award N/A
Clozapine vs Risperidone
for Psychosis
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.
Recruiting2 awards Phase 47 criteria
More about Carol A Tamminga, MD
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Carol A Tamminga, MD has experience with
- Deep Brain Stimulation
- Clozapine
- Risperidone
- Electroconvulsive Therapy
- Magnetic Seizure Therapy
Breakdown of trials Carol A Tamminga, MD has run
High Risk for Psychosis
Bipolar disorder
Schizoaffective Disorder
Depression
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carol A Tamminga, MD specialize in?
Carol A Tamminga, MD focuses on Schizophrenia and High Risk for Psychosis. In particular, much of their work with Schizophrenia has involved treating patients, or patients who are undergoing treatment.
Is Carol A Tamminga, MD currently recruiting for clinical trials?
Yes, Carol A Tamminga, MD is currently recruiting for 2 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Carol A Tamminga, MD has studied deeply?
Yes, Carol A Tamminga, MD has studied treatments such as Deep Brain Stimulation, Clozapine, Risperidone.
What is the best way to schedule an appointment with Carol A Tamminga, MD?
Apply for one of the trials that Carol A Tamminga, MD is conducting.
What is the office address of Carol A Tamminga, MD?
The office of Carol A Tamminga, MD is located at: University of Texas Southwestern Medical Center, Dallas, Texas 75390-9127 United States. This is the address for their practice at the University of Texas Southwestern Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.